Analyst Activity – Credit Suisse Group Reiterates Buy on Foamix Pharmaceuticals (NASDAQ:FOMX)

ME Staff
-
0

Analyst Ratings For Foamix Pharmaceuticals (NASDAQ:FOMX)

Today, Credit Suisse Group reiterated its Buy rating on Foamix Pharmaceuticals (NASDAQ:FOMX) with a price target of $9.00.

There are 2 buy ratings on the stock.

The current consensus rating on Foamix Pharmaceuticals (NASDAQ:FOMX) is Buy (Score: 3.00) with a consensus target price of $14.50 per share, a potential 161.73% upside.

Some recent analyst ratings include

  • 7/19/2017-Credit Suisse Group Reiterated Rating of Buy.
  • 8/13/2016-Guggenheim Reiterated Rating of Buy.


    Recent Trading Activity for Foamix Pharmaceuticals (NASDAQ:FOMX)
    Shares of Foamix Pharmaceuticals closed the previous trading session at 5.54 down -0.21 -3.65% with 123,520 shares trading hands.